[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"doppler-echocardiography\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:doppler-echocardiography":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100631250","coronoary-microcirculation-analysis-network-100631250",false,"NCT07498231","COronoary Microcirculation Analysis NETwork","Assessment of Risk Factors for Coronary Circulatory and Microcirculatory Disorders, Comparison of Invasive and Non-Invasive Diagnostic Methods, and Evaluation of the Impact of Individualized Pharmacotherapy Optimization on Patients' Quality of Life","COMA-NET","Inclusion Criteria:\n\na. Chronic coronary syndrome c. Anginal symptoms \\> CCS class I or angina equivalent d. Myocardial ischemia confirmed by non-invasive testing e. Provision of informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Angiographically significant coronary artery stenosis or FFR \\\u003C 0.8\n2. Renal insufficiency with eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²\n3. Left ventricular ejection fraction \\\u003C 40%\n4. Hypertrophic cardiomyopathy\n5. Acute coronary syndrome within \\\u003C 90 days\n6. Percutaneous coronary intervention (PCI) within \\\u003C 90 days\n7. Previous coronary artery bypass grafting (CABG)\n8. Anemia \\\u003C 10 g\u002FdL or thrombocytopenia \\\u003C 100,000\u002FµL\n9. Intraventricular conduction disturbances preventing ST-T segment assessment\n10. Severe concomitant valvular heart disease\n11. Active malignancy\n12. Type 1 diabetes mellitus\n13. Coronary artery anatomical abnormalities precluding assessment using PressureWire X (myocardial bridge causing \\> 50% luminal narrowing of the investigated vessel, severe coronary tortuosity, inability to properly cannulate coronary ostia)\n14. Pregnancy\n15. Heart failure ≥ NYHA class III\n16. Asthma or COPD with severe irreversible airflow obstruction\n17. Atrial fibrillation\n18. Second- or third-degree atrioventricular block without pacemaker implantation (IPG)\n19. Manifest pre-excitation on ECG or history of AVRT episodes without prior ablation of the accessory pathway","ALL","18 Years","75 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"NA","COMA.NET (Coronary Microcirculation Analysis Network) is a prospective, randomized, open-label, parallel-group clinical trial designed to determine whether endotype-guided pharmacotherapy is superior to standard care in improving quality of life in patients with ischemia with non-obstructive coronary arteries. Approximately 180-190 participants with objective ischemia will be randomized to either the control or the intervention group.\n\nPharmacotherapy based on the endotype established during intracoronary assessment will be introduced in the intervention arm of the study. The primary endpoint is the change in the Seattle Angina Questionnaire (SAQ) score from baseline to 3 months. Secondary endpoints include the diagnostic accuracy of transthoracic echocardiographic coronary flow velocity reserve (CFVR), the incidence of adverse events, associations between biomarkers and coronary microvascular dysfunction (CMD), and the identification of risk factors for specific CMD endotypes.\n\nParticipants will undergo invasive functional evaluation of the coronary microcirculation, measurement of echocardiographic CFVR, and analysis of selected circulating biomarkers. The study cohort will be followed up at three and six months and will include reassessment of quality of life (Seattle Angina Questionnaire, EuroQol 5-Dimensions 5-Level questionnaire, 12-item Short Form Health Survey), anxiety (Generalized Anxiety Disorder-7 score), and functional status (6-minute walk test).\n\nThe study began in October 2025. Primary completion is anticipated in October 2027, and the overall study completion date is expected in March 2028.",[28,29,30,31,32,33,34],"Coronary Artery Disease","Microcirculation Resistance","Microcirculation; Biomarkers; Myocardial Ischemia","Microcirculatory Dysfunction","Microcirculatory Status","Echocardiography","Doppler Echocardiography",[36,37,38,39,40,41,42],"coma.net","coma-net","coronary microcirculation","ANOCA","INOCA","angina with non-obstructive coronary arteries","ischemia with non-obstructive coronary arteries","RECRUITING","2026-04-02",{"date":46,"type":47},"2026-04-08","ACTUAL",{"date":49,"type":47},"2025-10-10",{"date":51,"type":22},"2028-03",{"name":53,"class":54},"Medical University of Bialystok","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":63,"minAge":18,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":23,"phases":67,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":55},"100574338","doppler-echocardiography-versus-clinical-targets-guided-therapy-on-the-outcome-of-postpartum-septic-shock-100574338","NCT06757985","Doppler Echocardiography Versus Clinical Targets Guided Therapy on the Outcome of Postpartum Septic Shock.","Doppler Echocardiography Versus Clinical Targets Guided Therapy on the Outcome of Postpartum Septic Shock, a Randomized Controlled Trial","Inclusion Criteria:\n\n* postpartum women, within 6 weeks following delivery\n* meeting the third international consensus definitions for septic Shock (2016) (Sepsis-3): acute persisting hypotension requiring vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mm Hg and having a serum lactate \\> 2 mmol\u002FL (18 mg\u002FdL) despite adequate volume resuscitation\n\nExclusion Criteria:\n\n* Patient refusal\n* History of any chronic cardiac disease\n* Requirement for immediate surgery\n* Hypotension attributable to another cause\n* Do-not-resuscitate status\n* Contraindication to central venous catheter placement\n* Difficult transthoracic echocardiographic evaluation\n* Primary cardiogenic cause of shock, instead of sepsis.","FEMALE","45 Years",{"count":66,"type":22},60,[25],"Postpartum sepsis is widely known as a preventable main cause of maternal morbidity and mortality. According to the World Health Organization, approximately 11% of the estimated maternal deaths worldwide were attributed to sepsis. Recent global assessments indicate that obstetric infections rank as the third most prevalent cause of maternal death, with a prevalence mainly observed in low- and middle-income nations.",[34,70],"Postpartum Septic Shock","NOT_YET_RECRUITING","2025-01-03",{"date":74,"type":47},"2025-01-06",{"date":76,"type":22},"2024-12-30",{"date":78,"type":22},"2026-11-30",{"name":80,"class":54},"Assiut University"]